CSPC Pharmaceutical Group Limited CSPCY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 105.93% | -3.20% | -1.87% | 3.39% | -14.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.93% | -3.20% | -1.87% | 3.39% | -14.16% |
| Cost of Revenue | 5.47% | -0.09% | 6.31% | 10.05% | 5.35% |
| Gross Profit | 162.46% | -4.73% | -5.68% | 0.21% | -22.26% |
| SG&A Expenses | 28.35% | 5.19% | -15.11% | -6.11% | -26.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.59% | 4.85% | 2.26% | 4.45% | -7.62% |
| Operating Income | 537.91% | -32.45% | -31.81% | -3.13% | -36.22% |
| Income Before Tax | 414.19% | -33.70% | -38.43% | 25.49% | -24.06% |
| Income Tax Expenses | 262.02% | -15.20% | -43.44% | 15.27% | -24.46% |
| Earnings from Continuing Operations | 448.37% | -37.43% | -35.64% | 28.11% | -23.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3,694.64% | -91.72% | 123.32% | -81.83% | 33.10% |
| Net Income | 419.88% | -38.90% | -31.60% | 27.20% | -23.88% |
| EBIT | 537.91% | -32.45% | -31.81% | -3.13% | -36.22% |
| EBITDA | 420.29% | -25.81% | -21.53% | 1.21% | -29.80% |
| EPS Basic | 419.23% | -38.42% | -30.30% | 31.11% | -20.73% |
| Normalized Basic EPS | -- | -35.34% | -- | 59.09% | -- |
| EPS Diluted | 417.69% | -38.42% | -30.30% | 31.11% | -20.73% |
| Normalized Diluted EPS | -- | -35.34% | -- | 59.09% | -- |
| Average Basic Shares Outstanding | -0.16% | -0.39% | -1.40% | -2.42% | -3.46% |
| Average Diluted Shares Outstanding | 0.17% | -0.39% | -1.40% | -2.42% | -3.46% |
| Dividend Per Share | 29.38% | -- | 34.53% | -- | -14.08% |
| Payout Ratio | -- | -- | -- | -- | -- |